on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Junction Therapeutics, a clinical stage biotech developing siRNA technology for the safe controlled modulation of blood brain barrier (BBB) permeability. This will revolutionise the treatment of neurological conditions by selectively allowing small molecules to enter the brain as treatment as well as allowing pathological molecules to be removed. The BBB expresses high levels of tight-junction proteins, claudin-5 and occludin to prevent unwanted entry of solutes. Administration of siRNA complexes targeting claudin-5 (JT-01) and occludin + claudin-5 (JT-02) selectively and reversibly loosens the tight junction barrier component, this therapy renders the BBB reversibly permeable to compounds up to 10 kD for up to 36 hours. At Junction, we have taken advantage of previous issues with siRNA technology as we need only 30% suppression and can be delivered by peripheral injection for BBB permeability. Our completed FDA-observed GLP primate studies shown Glioblastoma Multiforme as a disease model to demonstrate JT-01 as an effective BBB drug delivery platform and treatment of cerebral edema. Our JT-02 programme is shown promise halting neurological conditions and symptoms such as reducing Aβ1-40 levels and increase cognitive ability in Alzheimer’s Disease model over 12 months of treatment. Our treatments are safe and no significant toxicity has been found.
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Juvabis is a recent Universität Zürich spin-off with a strong ETH-UZH IP portfolio in the field of anti-infective therapeutics. Juvabis is pre-seed stage currently operating out of UZH premises, about to enter the CTI coaching programme and bound to attract series A funding by the end of this year.
Albeit being a young startup company, our preclinical portfolio of leads has already been quite successful with the first candidate bound to enter non-clinical GLP tox in October 2017, thanks to an accelerator-type of partnership with the IMI ND4BB programme (http://nd4bb-enable.eu).
Responsive Web Design powered by 